Solace shutters Boston-based office

Solace Pharmaceuticals has closed its Cambridge, MA-based office following disappointing results from a Phase II trial of its pain treatment pill SLC022. The company was founded in 2006 and has so far raised $15 million in capital. Solace's four remaining full-time employees are based out the company's office in Canterbury, U.K. Report

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.